Due to its simplicity and proven superior performance, the quantitative Faecal Immunochemical Test (FIT) is currently considered the best non-invasive Faecal Occult Blood (FOB) test for CRC screening.
In Europe, colorectal cancer (CRC) is the most prevalent of all tumours, with 471,000 cases diagnosed per year and second only to lung cancer in terms of deaths. Yet studies show that it is possible to reduce mortality significantly when one adopts population-based CRC screening programmes.
A European Parliament resolution calls for the adoption of primary prevention and early diagnosis through screening. Some European member states have already started population-based screening programmes, either on a national or regional scale. Populations between 50 and 74 years of age are often eligible for and invited to participate in CRC screening programmes to detect bowel cancer early on.
As FIT can detect blood in stool invisible to the naked eye, these tests are an effective triage for physicians when determining who will most likely benefit from further invasive investigation.
Sysmex provides unique FIT testing solutions for screening both asymptomatic populations (use of FIT as rule-in testing) and symptomatic patients (using FIT as rule-out testing).
The unique features of our FOBGold assay tubes make our FIT suitable for the widest possible range of lab settings and clinical needs.
Learn more by clicking on the information links below.
After lung and breast cancer, colorectal cancer is the third most common cancer worldwide. To accelerate early detection, European countries are now starting to implement population-based screening programmes with FIT (Faecal Immunochemical Testing).
The Netherlands have led the way for four years.